Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma

Immunology

Volumn 140, Issue 2, 2013, Pages 259-272

  Cycon, Kelly A ^a   Mulvaney, Kathleen ^b   Rimsza, Lisa M ^c   Persky, Daniel ^d   Murphy, Shawn P ^e  

^a ZeptoMetrix Corporation   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d YALE CANCER CENTER   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

Author keywords

B cells; Histone deacetylase inhibitor; Human; Lymphoma; MHC

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; HISTONE DEACETYLASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 TRANSACTIVATOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; BURKITT LYMPHOMA; CHORIOCARCINOMA; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONFORMATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; GENE REPRESSION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TRANSIENT TRANSFECTION;

B CELLS; HISTONE DEACETYLASE INHIBITOR; HUMAN; LYMPHOMA; MHC;

CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84883794500     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12136     Document Type: Article

References (72)

1. Rimsza LM, Farinha P, Fuchs DA, Masoudi H, Connors JM, Gascoyne RD. HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. Leuk Lymphoma 2007; 48:542-6.
2. Rimsza LM, Roberts RA, Miller TP et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004; 103:4251-8.
3. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1937-47.
4. Veelken H, Vik Dannheim S, Schulte Moenting J, Martens UM, Finke J, Schmitt-Graeff A. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol 2007; 18:931-9.
5. Wilkinson ST, Vanpatten KA, Fernandez DR et al. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. Blood 2012; 119:1459-67.
6. Lippman SM, Spier CM, Miller TP, Slymen DJ, Rybski JA, Grogan TM. Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. Mod Pathol 1990; 3:361-7.
7. List AF, Spier CM, Miller TP, Grogan TM. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence. Leukemia 1993; 7:398-403.
8. Stopeck AT, Gessner A, Miller TP, Hersh EM, Johnson CS, Cui H, Frutiger Y, Grogan TM. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res 2000; 6:3904-9.
9. Glimcher LH, Kara CJ. Sequences and factors: a guide to MHC class-II transcription. Annu Rev Immunol 1992; 10:13-49.
10. Harton JA, Ting JP. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol 2000; 20:6185-94.
11. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 1996; 14:301-31.
12. Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell 2002; 109(Suppl):S21-33.
13. Silacci P, Mottet A, Steimle V, Reith W, Mach B. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J Exp Med 1994; 180:1329-36.
14. Piskurich JF, Gilbert CA, Ashley BD, Zhao M, Chen H, Wu J, Bolick SC, Wright KL. Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-γ. Mol Immunol 2006; 43:519-28.
15. Zhao M, Flynt FL, Hong M et al. MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-γ. Mol Immunol 2007; 44:2923-32.
16. Ghosh N, Gyory I, Wright G, Wood J, Wright KL. Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells. J Biol Chem 2001; 276:15264-8.
17. Piskurich JF, Lin KI, Lin Y, Wang Y, Ting JP, Calame K. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat Immunol 2000; 1:526-32.
18. Chen H, Gilbert CA, Hudson JA, Bolick SC, Wright KL, Piskurich JF. Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter. Mol Immunol 2007; 44:1461-70.
19. Tooze RM, Stephenson S, Doody GM. Repression of IFN-γ induction of class II transactivator: a role for PRDM1/Blimp-1 in regulation of cytokine signaling. J Immunol 2006; 177:4584-93.
20. Green MR, Yoon H, Boss JM. Epigenetic regulation during B cell differentiation controls CIITA promoter accessibility. J Immunol 2006; 177:3865-73.
21. Holling TM, van Eggermond MC, Jager MJ, van den Elsen PJ. Epigenetic silencing of MHC2TA transcription in cancer. Biochem Pharmacol 2006; 72:1570-6.
22. Wright KL, Ting JP. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 2006; 27:405-12.
23. Morimoto Y, Toyota M, Satoh A et al. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-γ in haematopoietic tumour cells. Br J Cancer 2004; 90:844-52.
24. Satoh A, Toyota M, Ikeda H et al. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-γ-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 2004; 23:8876-86.
25. van den Elsen PJ, Holling TM, van der Stoep N, Boss JM. DNA methylation and expression of major histocompatibility complex class I and class II transactivator genes in human developmental tumor cells and in T cell malignancies. Clin Immunol 2003; 109:46-52.
26. Ni Z, Karaskov E, Yu T et al. Apical role for BRG1 in cytokine-induced promoter assembly. Proc Natl Acad Sci U S A 2005; 102:14611-6.
27. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26:5541-52.
28. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009; 107:600-8.
29. Min SK, Koh YH, Park Y, Kim HJ, Seo J, Park HR, Cho SJ, Kim IS. Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas. Korean J Pathol 2012; 46:142-50.
30. Gupta M, Han JJ, Stenson M, Wellik L, Witzig TE. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 2012; 26:1356-64.
31. Chou SD, Khan AN, Magner WJ, Tomasi TB. Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int Immunol 2005; 17:1483-94.
32. Magner WJ, Kazim AL, Stewart C et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 2000; 165:7017-24.
33. Mombelli M, Lugrin J, Rubino I, Chanson AL, Giddey M, Calandra T, Roger T. Histone deacetylase inhibitors impair antibacterial defenses of macrophages. J Infect Dis 2011; 204:1367-74.
34. Roger T, Lugrin J, Le Roy D et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011; 117:1205-17.
35. Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Dinarello CA, Ferrara JL. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A 2004; 101:3921-6.
36. + regulatory T cells in rhesus macaques. Transplant Proc 2008; 40:459-61.
37. Tao R, de Zoeten EF, Ozkaynak E et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13:1299-307.
38. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769-84.
39. Crump M, Coiffier B, Jacobsen ED et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008; 19:964-9.
40. O'Connor OA, Heaney ML, Schwartz L et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006; 24:166-73.
41. Persky DO, Bernstein SH, Goldman B, Rimsza LM, Fisher RI, Miller TP. A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520. J Clin Oncol 2012; 30:e18536.
42. Bushway M, Cycon KA, Mulvaney K, Murphy SP. Coordinate loss of MHC class II expression in the diffuse large B cell lymphoma cell line OCI-Ly2 is due to a novel mutation in RFX-AP. Immunogenetics 2010; 62:109-16.
43. Cycon KA, Rimsza LM, Murphy SP. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL). Exp Hematol 2009; 37:184-94.
44. Rimsza LM, Chan WC, Gascoyne RD et al. CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. Haematologica 2009; 94:596-8.
45. Rimsza LM, Roberts RA, Campo E et al. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 2006; 107:1101-7.
46. Choi JC, Holtz R, Petroff MG, Alfaidy N, Murphy SP. Dampening of IFN-γ-inducible gene expression in human choriocarcinoma cells is due to phosphatase-mediated inhibition of the JAK/STAT-1 pathway. J Immunol 2007; 178:1598-607.
47. Holtz R, Choi JC, Petroff MG, Piskurich JF, Murphy SP. Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts. Biol Reprod 2003; 69:915-24.
48. Morris AC, Riley JL, Fleming WH, Boss JM. MHC class II gene silencing in trophoblast cells is caused by inhibition of CIITA expression. Am J Reprod Immunol 1998; 40:385-94.
49. Wilkinson ST, Fernandez DR, Murphy SP et al. Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. Leuk Lymphoma 2009; 50:1875-8.
50. Choi JC, Holtz R, Murphy SP. Histone deacetylases inhibit IFN-γ-inducible gene expression in mouse trophoblast cells. J Immunol 2009; 182:6307-15.
51. Piskurich JF, Linhoff MW, Wang Y, Ting JP. Two distinct γ interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor β. Mol Cell Biol 1999; 19:431-40.
52. Garcia JF, Roncador G, Garcia JF et al. PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica 2006; 91:467-74.
53. Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM et al. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica 2010; 95:1342-9.
54. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503-11.
55. Sarosiek KA, Nechushtan H, Lu X, Rosenblatt JD, Lossos IS. Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy. Br J Haematol 2009; 147:308-18.
56. Holling TM, Van der Stoep N, Van den Elsen PJ. Epigenetic control of CIITA expression in leukemic T cells. Biochem Pharmacol 2004; 68:1209-13.
57. Morris AC, Beresford GW, Mooney MR, Boss JM. Kinetics of a γ interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation. Mol Cell Biol 2002; 22:4781-91.
58. Ashraf U, Czuczman MS, Marvis C, Gibbs J, Hernandez-Ilizaliturri FJ. Entinostat (SNDX-275), a novel DAC inhibitor, is highly effective in rituximab-[chemotherapy]-sensitive or rituximab-[chemotherapy]-resistant lymphomas and has synergistic anti-tumor activity when combined with bortezomib. Blood 2009; 114:1435-6.
59. Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006; 107:4090-100.
60. Pike BL, Greiner TC, Wang X et al. DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia 2008; 22:1035-43.
61. Landmann S, Muhlethaler-Mottet A, Bernasconi L et al. Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. J Exp Med 2001; 194:379-91.
62. Conley BA, Wright JJ, Kummar S. Targeting epigenetic abnormalities with histone deacetylase inhibitors. Cancer 2006; 107:832-40.
63. Zika E, Greer SF, Zhu XS, Ting JP. Histone deacetylase 1/mSin3A disrupts γ-interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation. Mol Cell Biol 2003; 23:3091-102.
64. Khan N, Jeffers M, Kumar S et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008; 409:581-9.
65. Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G, Wintersberger E, Seiser C. Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 1999; 19:5504-11.
66. Suzuki M, Yamada T, Kihara-Negishi F, Sakurai T, Oikawa T. Direct association between PU.1 and MeCP2 that recruits mSin3A-HDAC complex for PU.1-mediated transcriptional repression. Oncogene 2003; 22:8688-98.
67. Ghosh N, Piskurich JF, Wright G, Hassani K, Ting JP, Wright KL. A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes. J Biol Chem 1999; 274:32342-50.
68. Cycon KA, Clements JL, Holtz R, Fuji H, Murphy SP. The immunogenicity of L1210 lymphoma clones correlates with their ability to function as antigen-presenting cells. Immunology 2009; 128:e641-51.
69. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995; 181:619-29.
70. + T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 2004; 64:1867-74.
71. Khan AN, Magner WJ, Tomasi TB. An epigenetically altered tumor cell vaccine. Cancer Immunol Immunother 2004; 53:748-54.
72. Maeda T, Towatari M, Kosugi H, Saito H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 2000; 96:3847-56.